{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-003868","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.098532+00:00","generated_at":"2026-06-04T06:15:13.404329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set","bullets":["Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.","Full year 2023 net loss $10.1M ($1.58/share) vs $13.2M ($4.56) in 2022.","Cash and cash equivalents $2.8M as of December 31, 2023.","Installed first TAEUS system at King's College Hospital UK for 75-subject clinical study.","FDA De Novo review ongoing; in-person meeting scheduled for Q2 2024 after Additional Information request."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-003868","json":"https://secwatch.observer/filing/0001654954-24-003868.json","markdown":"https://secwatch.observer/filing/0001654954-24-003868.md","text":"https://secwatch.observer/filing/0001654954-24-003868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:15:13.404329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d14926870e9b03dc2b04f197e6f28581bd375aeb","claim":"ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.","evidence_excerpt":"Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f15f2b53a2d20a947ebaac528df3ecdd4b83fea6","claim":"ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.","evidence_excerpt":"Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss in 2023 was $10.1 million, or $1.58 per share"},{"label":"EPS","value":"$1.58 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}